Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 15/20 | 0.77 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.45 |
| ▸ | NEK2 | P51955 | 1/20 | 0.45 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.45 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.45 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13152267 | 0.87 | MET (0.77) | METHDAC1 | |
| SCHEMBL3084164 | 0.87 | MET (1.00) | METMEN1KMT2ACHEK1NEK2 | |
| SCHEMBL3099578 | 0.85 | MET (0.73) | METHDAC1MEN1KMT2A | |
| SCHEMBL1952616 | 0.84 | MET (0.65) | METHDAC1MEN1KMT2ACHEK1 | |
| SCHEMBL3089599 | 0.84 | MET (0.77) | METHDAC1MEN1KMT2A | |
| SCHEMBL3099160 | 0.82 | MET (0.81) | METHDAC1 | |
| SCHEMBL3088619 | 0.80 | MET (0.69) | MET | |
| SCHEMBL3088627 | 0.80 | MET (1.00) | METMEN1KMT2ACHEK1NEK2 | |
| SCHEMBL3078895 | 0.80 | MET (0.77) | METMEN1KMT2A | |
| SCHEMBL13152176 | 0.80 | MET (0.77) | METHDAC1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2754660-B1 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2016-11-02 | — | — | EP | claimed |
| US-8927540-B2 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2015-01-06 | — | — | US | claimed |
| US-8921357-B2 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2014-12-30 | — | — | US | claimed |
| EP-2164843-B1 | PYRIDAZINONE DERIVATES | MERCK PATENT GMBH (DE) | 2014-10-29 | — | — | EP | claimed |
| US-20130184260-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-07-18 | — | — | US | claimed |
| US-20130184261-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-07-18 | — | — | US | claimed |
| US-20100234354-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-16 | — | — | US | claimed |
| EP-2754660-B1 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2016-11-02 | — | — | EP | disclosed |
| EP-2164843-B1 | PYRIDAZINONE DERIVATES | MERCK PATENT GMBH (DE) | 2014-10-29 | — | — | EP | disclosed |
| CN-101743241-B | Pyridazinone derivates | MERCK PATENT GMBH | 2013-12-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184261-A1 | PYRIDAZINONE DERIVATIVES | MET, RET, ERBB2 | MET 1/4885HDAC1 1144/4885MEN1 164/4885 |
| US-20130184260-A1 | PYRIDAZINONE DERIVATIVES | MET, RET, ERBB2 | MET 1/4885HDAC1 1182/4885MEN1 173/4885 |
| US-20100234354-A1 | PYRIDAZINONE DERIVATIVES | MET, RET, ERBB2 | MET 1/4885HDAC1 1320/4885MEN1 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.